Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Smoldering Plasma Cell Myeloma: early-phase trial registry
5 of 10 indexed Smoldering Plasma Cell Myeloma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,724 of 28,707 conditions by registered trial count.
10 US clinical trials · 5 currently recruiting · #1,724 of 28,707 conditions by registered trial count
Smoldering Plasma Cell Myeloma: 10 US clinical trials tracked, 5 recruiting.
Smoldering Plasma Cell Myeloma is the subject of 10 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 4 of these trials.
Enrollment posture brief
Registry condition smoldering-plasma-cell-myeloma
OPEN 5 | RECR 50% | LATE 1 | EARLY 6 | RANK #1724 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Smoldering Plasma Cell Myeloma lists 5 open slots (50% of 10 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Smoldering Plasma Cell Myeloma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Smoldering Plasma Cell Myeloma is recruiting above its size-band peers.
5 of 10 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Smoldering Plasma Cell Myeloma research.
M.D. Anderson Cancer Center accounts for 4 of 10 trials (40%). 6 distinct sponsors appear on at least one study for this condition label.
-
Most Smoldering Plasma Cell Myeloma trials plan to enrol fewer than 100 people.
Median target enrolment is 68 among the 10 trials that report a genuine target (sentinel values excluded). 6 of those (60%) plan for fewer than 100 participants.
-
Smoldering Plasma Cell Myeloma research is mostly interventional.
8 interventional and 2 observational studies make up this index (80% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
10 total, page 1 of 1
Quality of Life in Patients With Asymptomatic Monoclonal Gammopathies
M.D. Anderson Cancer Center
NCT05136807
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
ECOG-ACRIN Cancer Research Group
NCT03937635
Observational Prospective Research Study In Monoclonal Gammopathies leadINg to Myeloma
M.D. Anderson Cancer Center
NCT02726750
Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma
Roswell Park Cancer Institute
NCT05312255
Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma
Emory University
NCT04776395
Isatuximab With or Without Lenalidomide in Patients With High Risk Smoldering Multiple Myeloma (ISAMAR)
M.D. Anderson Cancer Center
NCT02960555
Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients
City of Hope Medical Center
NCT05014646
Pembrolizumab in Treating Patients With Intermediate or High-Risk Smoldering Multiple Myeloma
M.D. Anderson Cancer Center
NCT02603887
Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma
City of Hope Medical Center
NCT04370483
Lenalidomide and Dexamethasone With or Without Anakinra in Treating Patients With Early Stage Multiple Myeloma
Mayo Clinic
NCT02492750
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 3 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Smoldering Plasma Cell Myeloma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Smoldering Plasma Cell Myeloma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Smoldering Plasma Cell Myeloma page
10 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 5 Smoldering Plasma Cell Myeloma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- M.D. Anderson Cancer Center sponsors the most Smoldering Plasma Cell Myeloma trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Smoldering Plasma Cell Myeloma condition card totals 10 registered trials; most-linked intervention Quality-of-Life Assessment; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.